

Oral presentation

Open Access

Polypharmacy in bipolar disorder: does it make sense?

Andreas Erfurth* and Anastasios Konstantinidis

Address: Medical University of Vienna, Austria

* Corresponding author

from International Society on Brain and Behaviour: 3rd International Congress on Brain and Behaviour
Thessaloniki, Greece. 28 November – 2 December 2007

Published: 17 April 2008

Annals of General Psychiatry 2008, **7**(Suppl 1):S48 doi:10.1186/1744-859X-7-S1-S48

This abstract is available from: <http://www.annals-general-psychiatry.com/content/7/S1/S48>

© 2008 Erfurth and Konstantinidis; licensee BioMed Central Ltd.

Bipolar disorders represent an illness not easily treated by monotherapy. Approximately 2/3 of patients are not adequately responsive to lithium monotherapy and the great majority of patients require (and get) additional medication: additional mood stabilizers [1], antipsychotics [2], antidepressants, antimanic and/or hypnotic substances [3,4]. These traditional additional drugs are associated with potential problems. Antidepressants may precipitate mixed states or mania and/or cause cycle acceleration and rapid cycling. Conventional neuroleptics are associated with switching into depression, and clearly increase the individual risk of extrapyramidal symptoms, such as tardive dyskinesia. Polypharmacy is associated with the risk of unwanted pharmacological interactions: specific risks in antibipolar treatment are discussed.

References

1. Goodwin FK: **Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder.** *J Clin Psychiatry* 2003, **64**(Suppl 5):18-24.
2. Bowden CL: **Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder.** *J Clin Psychiatry* 2005, **66**(Suppl 3):12-9.
3. Wolfsperger M, Greil W, Rossler W, Grohmann R: **Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004.** *J Affect Disord* 2007, **99**(1-3):9-17.
4. Grohmann R, Engel RR, Geissler KH, Ruther E: **Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study.** *Pharmacopsychiatry* 2004, **37**(Suppl 1):S27-38.